Medication Rules of National Patented Traditional Chinese Medicine Compound in the Treatment of Aplastic Anemia Based on Data Mining
OBJECTIVE:To analyze the medication and compatibility rules of national patented traditional Chinese medicine compound in the treatment of aplastic anemia based on data mining,so as to provide reference for clinical practice and new drug development.METHODS:Patents of traditional Chinese medicine compound in the treatment of aplastic anemia were extracted from the National Patent Database till Jun.30th,2023.According to the inclusion and exclusion criteria,all data were of screened,the analysis database was established.The ancient and modern medical record cloud platform was used to analyze drug attributes such as the four Qi and five flavors,meridian tropism,and efficacy.Apriori algorithm in IBM SPSS Modeler 18.0 software was used to perform association rule analysis on high-frequency drugs.Cluster analysis of high-frequency drugs was performed by the inter group connectivity method in SPSS Statistics 19.0 software.RESULTS:A total of 135 traditional Chinese medicine compound patents were obtained for the treatment of aplastic anemia,including 395 types of traditional Chinese medicine,with a total frequency of 1886 times of use.Among them,there were 25 high-frequency drugs,such as Angelicae sinensis radix,Hedysarum multijugum maxim,Rehmanniae radix praeparata,Lycii fructus,Spatholobus suberectus dunn and licorice.The properties of the drugs used were mostly warm and calm,mainly concentrated in three types of medicinal flavors:sweet,bitter and spicy.The drugs were mostly classified as liver,kidney and spleen meridians,with the main efficacy being tonifying deficiency drugs,supplemented by blood activating and stasis removing drugs,as well as astringent and hemostatic drugs,heat clearing and blood cooling drugs.Among the tonifying deficiency drugs,Qi tonifying drugs were used most frequently.There were 22 association rules for the combination of medicinal flavors within 4 flavors.Commonly used drug combination included Atractylodes macrocephala koidz-Rehmanniae radix praeparata-Angelicae sinensis radix,Poria cocos-Atractylodes macrocephala koidz-Angelicae sinensis radix-Rehmanniae radix praeparata,Poria cocos-Rehmanniae radix praeparata-Angelicae sinensis radix-Atractylodes macrocephala koidz.Cluster analysis obtained 4 groups of core drug combination,the first group mainly included Atractylodes macrocephala koidz,Poria cocos,Codonopsis radix,Rehmanniae radix praeparata,ass hide glue and Radix salviae.The second group mainly included Fructus ligustri lucidi,Ecliptae herba,Lycii fructus,Cuscutae semen and licorice.The third group mainly included Angelicae sinensis radix,Hedysarum multijugum maxim,Epimrdii herba,Rehmanniae radix praeparata,Rhizoma Dioscoreae,Paeoniae Radix Alba and Cornus officinalis sieb.The fourth group mainly included Agrimonia eupatoria,deer antler gum and Spatholobus suberectus dunn.CONCLUSIONS:Medication rules of national patented traditional Chinese medicine compound in the treatment of aplastic anemia mainly focus on tonifying deficiency,while following the treatment principles of"tonifying Qi and blood,nourishing Yin and Yang,nourishing blood and activating blood,clearing heat and detoxifying,cooling blood and stopping bleeding",which can provide reference for the research and development of new drugs.
Aplastic anemiaTraditional Chinese medicine compoundNational patentsData miningMedication rules
国家科技期刊平台
NSTL
万方数据
